durvalumab,atezolizumab,serplulimab
astrazeneca,medsir,roche,fosun pharmaceuticals
['durvalumab', 'atezo', 'serplulimab', 'sclc', 'medsir']
dr. cheng shares ph 3 astrum005:serplulimab+ct vs ct in untreated pts with extensive-stage sclc -statistically longer mos (15.4 vs 10.9m,hr 0.63) &amp; mpfs (5.8 vs. 4.3m;hr 0.47) -benefit in all subsets
-after atezolizumab &amp; durvalumab, another chemo-io option in es sclc! #asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc